Back to Search
Start Over
Supplementary Table 2 from A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Table 2. Summary of serious adverse events.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....4a9e4994bcd32bf3f650bc9bb6911ec4